Turn Therapeutics (TTRX) Net Cash Flow (2024 - 2026)

Turn Therapeutics' Net Cash Flow history runs 3 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 782.0% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $8.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $4.2 million, up 1451.0% from the prior year.
• Net Cash Flow grew to $6.2 million in Q1 2026 per TTRX's latest filing, from $1.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $6.2 million in Q1 2026 and bottomed at $83819.0 in Q4 2024.
• The 3-year median for Net Cash Flow is $1.3 million (2025), against an average of $2.2 million.
• Across the five-year window, Net Cash Flow soared 2210.04% in 2025 and surged 782.0% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at $83819.0 in 2024, then surged by 2210.04% to $1.9 million in 2025, then soared by 218.88% to $6.2 million in 2026.
• Per Business Quant, the three latest TTRX Net Cash Flow figures stand at $6.2 million (Q1 2026), $1.9 million (Q4 2025), and $700034.0 (Q1 2025).